A controversial ruling by the US Court of Appeals for the Federal Circuit over generic labeling carve-outs should be reheard “en banc” by the full court, to correct a misinterpretation of the rules around so-called skinny labels, the Association for Accessible Medicines has urged in an amicus brief.
The case involving GlaxoSmithKline and Teva over Coreg (carvedilol) made waves earlier this year when a split appeals court decision...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?